RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Science Translational Medicine

• Publication date

  2017-09-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.aan0241PMID 28954926PMCID PMC5830187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.

  2017cited by this paper
• Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.

  2016cited by this paper
• Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection.

  2016cited by this paper
• Dissonant health transition in the states of Mexico, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2016cited by this paper
• Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

  2016cited by this paper
• HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

  2015cited by this paper
• Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection

  2015cited by this paper
• Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors

  2015cited by this paper
• Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2015cited by this paper
• Global , regional , and national age – sex specifi c all-cause and cause-specifi c mortality for 240 causes of death , 1990 – 2013 : a systematic analysis for the Global Burden of Disease Study 2013

  2015cited by this paper
• HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

  2013cited by this paper
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

  2013cited by this paper
• Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.

  2012cited by this paper
• The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.

  2012cited by this paper
• Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

  2011cited by this paper
• A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B

  2010cited by this paper
• Clonal Expansion of Normal-Appearing Human Hepatocytes during Chronic Hepatitis B Virus Infection

  2010cited by this paper
• Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

  2010cited by this paper
• RNA-Seq: a revolutionary tool for transcriptomics

  2009cited by this paper
• The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection

  2009cited by this paper
• Posttranscriptional control of HBV gene expression.

  2008cited by this paper
• HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

  2008cited by this paper
• Detection of Clonally Expanded Hepatocytes in Chimpanzees with Chronic Hepatitis B Virus Infection

  2008cited by this paper
• Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

  2007cited by this paper
• Vaccines and immunotherapies against hepatitis B and hepatitis C viruses

  2007cited by this paper
• Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection

  2007cited by this paper
• Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus

  2007cited by this paper
• Stealth and Cunning: Hepatitis B and Hepatitis C Viruses

  2005cited by this paper
• Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients

  2004cited by this paper
• A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.

  2004cited by this paper
• Immunogenicity and Tolerogenicity of Hepatitis B Virus Structural and Nonstructural Proteins: Implications for Immunotherapy of Persistent Viral Infections

  2002cited by this paper
• Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages.

  2001cited by this paper
• Structural organization of the hepatitis B virus minichromosome.

  2001cited by this paper
• Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators.

  1994cited by this paper
• Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA

  1991cited by this paper
• Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA

  1991cited by this paper
• Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

  1990cited by this paper
• Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection.

  1990cited by this paper
• Integration of HBV-DNA may not be a prerequisite for the maintenance of the state of malignant transformation. An analysis of 110 liver biopsies.

  1986influential reference
• Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

  1986cited by this paper
• HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS. A Prospective Study of 22 707 Men in Taiwan

  1981cited by this paper
• Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

  1981cited by this paper

• Anti-Interferon-α Antibodies and HBsAg Seroclearance during Peginterferon-α Therapy in Chronic Hepatitis B.

  2026cites this paper
• Nanoparticle approaches for hepatitis therapy and clinical translation

  2026cites this paper
• Novel Long‐Read Sequencing Method for Characterisation of Hepatitis B Transcripts Show High Expression of Chimeric HBV/Human RNA

  2026cites this paper
• Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches

  2026cites this paper
• Detection and characterization of Hepatitis B virus double-stranded linear DNA-derived covalently closed circular DNA in chronic hepatitis B patients.

  2026cites this paper
• A retrospective study of preoperative HBsAg levels predicting recurrence after curative resection in patients with HBV-associated hepatocellular carcinoma

  2026cites this paper
• Virus de l’hépatite B

  2026cites this paper
• Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models

  2026cites this paper
• The promise of epigenetic editing strategies in functionally curing chronic hepatitis B virus infections

  2026cites this paper
• Circular nucleic acids at the host-virus interface: from immune modulation to therapeutic innovation

  2026cites this paper
• Spatial-Quantitative Profiling of Intrahepatic HBsAg Heterogeneity and Clustered Distribution in Chronic HBV Infection

  2026cites this paper
• Overview of gene editing strategies against HBV.

  2026cites this paper
• Hepatocyte-Targeted Drug Delivery Strategies for Chronic Hepatitis B: Overcoming Delivery Barriers Toward Functional Cure.

  2026cites this paper
• The Intrinsically Disordered Region of HBx and Virus–Host Interactions: Uncovering New Therapeutic Approaches for HBV and Cancer

  2025cites this paper
• The Progress and Evolving Trends in Nucleic-Acid-Based Therapies

  2025cites this paper
• Circulating Hepatitis B Virus (HBV) RNA and Conventional Markers in Treatment-Naive Persons With HBV in Senegal

  2025cites this paper
• Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection

  2025cites this paper
• Genomic medicine in hepatology: mechanisms and liver treatment strategies

  2025cites this paper
• Biology of Hepatitis B Virus DNA integration and its impact on antiviral R&D.

  2025cites this paper
• HBV Suppression by Nucleos(t)ide Analogues Reduces PD‐1 Expression on Liver‐Resident T Cells

  2025cites this paper
• Changes in HBcAg and HBsAg Expression Following Antiviral Therapy and Their Role in Outcome of Patients with Chronic Hepatitis B.

  2025cites this paper
• Large spatial variation of intrahepatic HDV RNA levels without association with HBV core or S RNA levels in HDV cirrhosis patients.

  2025cites this paper
• Development of a long-read high-throughput chromatin conformation capture method for evaluating both cis and trans interactions between integrated Hepatitis B Virus and host genomes

  2025cites this paper
• Update on combination therapies against HBV in clinical investigations.

  2025cites this paper
• Hepatitis B surface antigen is upregulated by HIV Tat in an HIV–hepatitis B virus co-infection model system

  2025cites this paper
• Swedish guidelines for the management and treatment of patients with hepatitis D (delta) virus infection 2025

  2025cites this paper
• Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers

  2025cites this paper
• Differential Intrahepatic Integrated HBV DNA Patterns Between HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B

  2025cites this paper
• Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B

  2025cites this paper
• HBcrAg Dynamic Change During Treatment Predicts HBsAg Loss in Pediatric Patients With Chronic Hepatitis B

  2025cites this paper
• Targeting HBV with RNA interference: Paths to cure.

  2025cites this paper
• Emerging Serum Biomarkers for Chronic Hepatitis B: Focus on Serum HBV RNA and HBcrAg

  2025influential citation
• Hepatitis B virus integration and hepatocarcinogenesis

  2025cites this paper
• Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure.

  2025cites this paper
• Recurrent integration of domestic cat hepatitis B virus DNA near feline CCNE1 supports an oncogenic role in hepatocellular carcinoma in cats

  2025cites this paper
• Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D

  2025cites this paper
• Longitudinal Profile of HBsAg Isoforms and Circulating Immune Complexes in the Natural History of Chronic Hepatitis B Infection

  2025cites this paper
• Dynamics of HBV biomarkers during nucleos(t)ide analog treatment: A 14-year study

  2025cites this paper
• The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma

  2025cites this paper
• Characteristics and outcomes of HBV-infected patients with HBsAg and anti- HBs coexistence

  2025cites this paper
• Epigenetic Drugs against Human DNA Viruses and Retroviruses.

  2025cites this paper
• Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α

  2025cites this paper
• Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure

  2025cites this paper
• Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs

  2025cites this paper
• Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance

  2025cites this paper
• The Role of Integrated HBV DNA in the Quest for a Cure in HIV/HBV co-infection

  2025cites this paper
• Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees

  2025influential citation
• Inactivation of the key ORFs of HBV for antiviral therapy by non-cleavage base editing.

  2025cites this paper
• HBcrAg and cirB‐RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg‐Negative Chronic Infection

  2025cites this paper
• Modeling covalently closed circular DNA dynamics in assessing chronic hepatitis B prognosis.

  2025cites this paper
• An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection

  2025cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection

  2025cites this paper
• Viral oncogenesis in cancer: from mechanisms to therapeutics

  2025cites this paper
• A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions

  2025cites this paper
• Residual Viral Expression in siRNA-Treated HBV-Replicating Cell and Mouse Models.

  2025cites this paper
• Novel digital droplet inverse PCR assay shows that natural clearance of hepatitis B infection is associated with fewer viral integrations

  2025cites this paper
• Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment

  2025cites this paper
• Assessing the virological response to direct-acting antiviral therapies in the HBV cure programme.

  2025cites this paper
• Chronic Hepatitis B: Current Management and Future Directions

  2025cites this paper
• In Vitro Transcribed Artificial Primary MicroRNA for the Inhibition of Hepatitis B Virus Gene Expression in Cultured Cells

  2025cites this paper
• Cracking the code of HBV persistence: cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver Abscesses

  2025influential citation
• Getting to HBV Cure - will new biomarkers help?

  2025cites this paper
• Investigational RNA Interference Agents for Hepatitis B

  2024influential citation
• Letter: Should HBV Therapy Be Stopped Based on HBsAg Level Alone?

  2024cites this paper
• New Insights on Hepatitis B Virus Viral Transcription in Single Hepatocytes

  2024influential citation
• Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?

  2024cites this paper
• Prospect of emerging treatments for hepatitis B virus functional cure

  2024cites this paper
• Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma

  2024cites this paper
• Baveno VII for HCC: Are we there yet?

  2024cites this paper
• Understanding and Targeting HBV Transcription and Post-Transcriptional Regulation

  2024cites this paper
• Modern etiotropic therapy of chronic viral hepatitis B

  2024cites this paper
• Characterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA

  2024influential citation
• The Pharmacokinetics and Liver-Targeting Evaluation of Silybin Liposomes Mediated by the NTCP/OCTN2 Dual Receptors.

  2024cites this paper
• Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment

  2024cites this paper
• Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift.

  2024cites this paper
• HBV Biomarkers and Their Role in Guiding Treatment Decisions

  2024influential citation
• S-pecial Delivery: Implications of HBV Surface Antigen Subviral particles Carrying microRNA Payloads.

  2024cites this paper
• Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome.

  2024cites this paper
• HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B

  2024influential citation
• Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection

  2024cites this paper
• Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion

  2024cites this paper
• Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

  2024cites this paper
• Hepatitis B surface antigen loss: what does integration have to do with a functional HBV cure?

  2024cites this paper
• The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy

  2024cites this paper
• Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

  2024cites this paper
• A molecular standard for circulating HBV RNA detection and quantification assays in patients with chronic hepatitis B

  2024cites this paper
• Long‐term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB

  2024cites this paper
• Profiles of HBcrAg and pgRNA in Pregnant Women With Chronic HBV Under Different Disease Phases and Antiviral Prophylaxis

  2024cites this paper
• Intracellular Host Restriction of Hepatitis B Virus Replication

  2024cites this paper
• An Overview of the Unfolded Protein Response (UPR) and Autophagy Pathways in Human Viral Oncogenesis.

  2024cites this paper
• Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy

  2024cites this paper
• Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis

  2024cites this paper
• Multi‐omics panoramic analysis of HBV integration, transcriptional regulation, and epigenetic modifications in PLC/PRF/5 cell line

  2024cites this paper
• An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity.

  2024cites this paper
• Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

  2024cites this paper
• Juveniles, young adults, and infants with hepatitis B virus infection: A genomic study

  2024cites this paper
• RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects

  2024cites this paper
• Toward a Functional Cure for Hepatitis B

  2024cites this paper
• The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice.

  2024cites this paper
• Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

  2024cites this paper